CA2235617A1 - Therapeutic preparation for the transdermal administration of active substances - Google Patents

Therapeutic preparation for the transdermal administration of active substances

Info

Publication number
CA2235617A1
CA2235617A1 CA 2235617 CA2235617A CA2235617A1 CA 2235617 A1 CA2235617 A1 CA 2235617A1 CA 2235617 CA2235617 CA 2235617 CA 2235617 A CA2235617 A CA 2235617A CA 2235617 A1 CA2235617 A1 CA 2235617A1
Authority
CA
Canada
Prior art keywords
active substances
therapeutic preparation
transdermal administration
additives
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2235617
Other languages
French (fr)
Other versions
CA2235617C (en
Inventor
Bodo Asmussen
Andreas Koch
Rudolf Matusch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19541260A external-priority patent/DE19541260A1/en
Application filed by Individual filed Critical Individual
Publication of CA2235617A1 publication Critical patent/CA2235617A1/en
Application granted granted Critical
Publication of CA2235617C publication Critical patent/CA2235617C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A therapeutic preparation for the transdermal application of active substances through the skin comprising additives causing an increase in the percutaneous absorption rate of active substances which can normally only insufficiently be absorbed transdermally is characterized by the fact that the additives are HMG-CoA-reductase-inhibitors.
CA 2235617 1995-11-06 1996-09-21 Therapeutic preparation for the transdermal administration of active substances Expired - Fee Related CA2235617C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19541260A DE19541260A1 (en) 1995-11-06 1995-11-06 Therapeutic preparation for transdermal application of active ingredients through the skin
DE19541260.5 1995-11-06
PCT/EP1996/004138 WO1997017061A1 (en) 1995-11-06 1996-09-21 Therapeutic preparation for the transdermal administration of active substances

Publications (2)

Publication Number Publication Date
CA2235617A1 true CA2235617A1 (en) 1997-05-15
CA2235617C CA2235617C (en) 2005-11-15

Family

ID=29403629

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2235617 Expired - Fee Related CA2235617C (en) 1995-11-06 1996-09-21 Therapeutic preparation for the transdermal administration of active substances

Country Status (1)

Country Link
CA (1) CA2235617C (en)

Also Published As

Publication number Publication date
CA2235617C (en) 2005-11-15

Similar Documents

Publication Publication Date Title
PL326497A1 (en) Pharmaceutic preparation for trancutaneous administration of active substances
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
EP0316065A3 (en) Improved transdermal drug delivery device
EP0224837A3 (en) Dermatologically active pharmaceutical compositions having liposomes as the substantive carriers
CA2181742A1 (en) Reduction of skin irritation during electrotransport delivery
AU537874B2 (en) Polyacrylate topical pharmaceutical
CA2132865A1 (en) Transdermal administration of oxybutynin
CA2276445A1 (en) Transdermal hormone-delivering therapeutic system
GB2316004A (en) Novel formulations for transdermal delivery of pergolide
YU48583B (en) Process for preparation of the formulation in the form of pill for oral dosage
CY2503B1 (en) Novel formulations for the transdermal administration of fluoxetine acetate and fluoxetine maleate.
CA2046014A1 (en) Reduction or prevention of skin irritation by drugs
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
IE873120L (en) User-activated transdermal therapeutic system
AU1950388A (en) Pharmaceutical formulation ensuring the transdermal absorption of the active ingredient and process for preparing same
EP0535237A4 (en) Composition for relieving skin irritation and external preparation for percutaneous adminstration containing the same
EP0693479A4 (en) Novel aconitine-like compound and antipyretic analgesic anti-inflammatory agent
CA2235617A1 (en) Therapeutic preparation for the transdermal administration of active substances
Torres et al. Allergic contact dermatitis from nitroglycerin and estradiol transdermal therapeutic systems.
CA2394471A1 (en) External preparation for treating pruritus
WO2001041771A3 (en) Transdermal system containing acetylsalicylic acid for treatment of migraine
EP0097953A3 (en) Synergistic compositions of nalbuphine and non-narcotic analgesic compounds
CA2251353A1 (en) Transdermal delivery device for azapirone compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130923